Every 8-K that Health In Tech, Inc. (HIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIT filings page.
Health In Tech, Inc. reported second quarter 2026 revenue of $8.1 million, down from $9.3 million a year earlier, primarily due to policy effective dates shifting while onboarding a new carrier. For the first half of 2026, revenue was $16.8 million versus $17.3 million in the prior-year period.
Management emphasized “contracted revenue” and “pipeline revenue” as leading indicators. Contracted revenue for the first half totaled $32.3 million, of which $17.3 million has already been recognized, with $14.0 million expected in the second half of 2026 and $1.0 million in 2027. Pipeline revenue was $66.3 million as of July 31, with an expected conversion rate of 15%–40%, supporting reaffirmed full-year 2026 revenue guidance of $45–$50 million.
Profitability weakened as the company invested in sales, marketing and technology. Adjusted EBITDA was $(1.3) million for the quarter and $(2.6) million for the first half, compared with positive results a year ago. Net loss was $(2.5) million in Q2 and $(4.1) million for the first half. Distribution partners grew to 933, up 19.9% year over year. Health In Tech ended the quarter with $6.5 million in cash and $11.8 million in working capital, and highlighted upcoming launches such as the HitRix marketplace and its Three-Year Rate Stabilization Program.
Health In Tech, Inc., an AI-driven marketplace for self-funded health plans for small and mid-sized businesses, furnished an investor presentation outlining its business model, market opportunity and recent financial performance. The company earns primarily fee-based revenue from self-funded plan administration and carrier underwriting, while stating it has no plan or underwriting risk exposure.
The presentation reaffirms 2026 revenue guidance of $45–$50 million, versus 2025 revenue of $33.3 million, supported by $32 million of contracted revenue from first-half 2026 activity and $66 million of pipeline revenue as of July 31, 2026. For Q2 2026, revenue was $8.1 million with a gross margin of 48.7%, compared with $9.3 million and 67.7% a year earlier, and the company reported a net loss and negative Adjusted EBITDA. Cash, working capital and stockholders’ equity all increased between June 30, 2025 and June 30, 2026. The company also highlights broker and partner growth and notes risk factors that include its liquidity position and its ability to continue as a going concern.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026 while reiterating its full-year outlook. For the quarter, total revenues were $8.1 million versus $9.3 million a year earlier, and the company moved from net income of $0.6 million to a net loss of $2.5 million. Gross profit declined to $3.9 million as costs and operating expenses increased, leading to an operating loss and negative Adjusted EBITDA of $1.3 million, compared with positive $1.6 million in the prior-year quarter.
For the first half of 2026, revenues were $16.8 million compared with $17.3 million in 2025, with a net loss of $4.1 million versus net income of $1.1 million. Operating cash flow was an outflow of $6.2 million. As of June 30, 2026, the company reported $32.3 million in Contracted Revenue and cash and cash equivalents of $6.5 million; total assets rose to $29.6 million and stockholders’ equity to $19.6 million, aided by a recent PIPE financing.
As of July 31, 2026, Pipeline Revenue totaled $66.3 million, including $64.4 million in quoting or binding stages that management estimates could convert into $3.1 million to $8.3 million of GAAP revenue in 2026 and additional revenue in 2027. Supported by this contracted and pipeline activity, the company reaffirmed its 2026 GAAP revenue guidance of $45 million to $50 million and highlighted strategic initiatives such as its Three-Year Rate Stabilization Program and the planned launch of its HitRix marketplace in the second half of 2026.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up about 9% year over year, as it shifts into an investment phase to support long-term growth. The company introduced new metrics to better explain its recurring business model and revenue visibility.
As of March 31, 2026, Contracted Revenue expected to be recognized over the remaining three quarters of 2026 was about $22.9 million, and first-quarter Platform Placed Plan Value reached $82 million in self-funded stop-loss plans placed through its platform. Management is reiterating full-year 2026 revenue guidance of $45–$50 million, implying roughly 35% to 50% growth.
Higher spending on sales, marketing, and product development drove an adjusted EBITDA loss of $1.3 million and a net loss of $1.6 million in the quarter. Operating expenses rose to $6.7 million, or 76% of revenue, as the company adds distribution capacity, enhances its AI-powered eDIYBS platform, and develops new offerings such as a Three-Year Rate Stabilization Program. A recent PIPE financing provided about $7 million in gross proceeds, leaving cash and equivalents at $10.3 million.
Health In Tech, Inc. presents an investor update highlighting its AI-powered marketplace that helps small and mid-sized employers access self-funded health plans paired with stop-loss insurance, while taking no plan or underwriting risk itself. The business earns recurring administrative fees and a share of stop-loss premiums.
Revenue grew from $19.5 million in 2024 to $33.3 million in 2025, with 2026 revenue guidance of $45–$50 million. First-quarter 2026 revenue rose to $8.8 million from $8.0 million, though Adjusted EBITDA shifted to a $(1.3) million loss as the company increases sales and marketing spending to drive future growth.
As of March 31, 2026, Health In Tech reported $10.3 million in cash and cash equivalents, $15.0 million in working capital and $21.6 million in stockholders’ equity. Business activity included $82.0 million of platform placed plan value, $22.9 million of contracted revenue for the remainder of 2026 and relationships with 896 brokers, third-party administrators and agencies.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up from $8.0 million a year earlier, driven mainly by higher fees revenue. The company posted a net loss of $1.6 million, compared with net income of $0.5 million in the prior-year quarter, as operating expenses rose sharply.
Adjusted EBITDA was a loss of $1.3 million versus positive $1.2 million a year ago. Management reiterated full-year 2026 revenue guidance of $45–$50 million, implying approximately 35% to 50% growth, supported by $22.9 million of contracted revenue as of March 31, 2026. A March 2026 private investment in public equity provided about $7.0 million in gross proceeds, lifting cash and cash equivalents to $10.3 million at quarter end.
Health In Tech, Inc. reported that Dustin Plantholt will depart from his role as Chief AI & Marketing Officer, effective April 30, 2026. The company states this change is part of a business transition and not due to any disagreement over operations, policies, or practices.
HITChain Inc., a subsidiary, entered into a Consulting Agreement dated May 1, 2026 with Plantholt Advisory Group LLC, owned and controlled by Mr. Plantholt. Under this arrangement, the consultant will receive monthly compensation and Mr. Plantholt will be granted 500,000 restricted shares of HITChain common stock, vesting in equal monthly installments over 12 months, subject to continued service. Either party may terminate the agreement with ten days’ prior written notice.
Health In Tech, Inc. furnished an investor presentation describing its AI-powered marketplace that helps small and mid-sized businesses access self-funded health plans without taking plan or underwriting risk. The company reported 2025 revenue of $33.3M, up from $19.5M in 2024, and 2025 adjusted EBITDA of $4.1M versus $2.3M a year earlier. As of December 31, 2025, it had 22,515 enrolled employees, 795 business clients, and 858 brokers and agencies, with stockholders’ equity of $17.1M. The presentation reiterates 2026 revenue guidance of $45M–$50M, highlights a fee-based model with no claims exposure, and emphasizes plans to drive growth through more brokers, products, and carrier relationships.
Health In Tech, Inc. completed a private investment in public equity financing, raising gross proceeds of approximately $7.0 million. The company issued 5,600,000 shares of common stock at $1.25 per share to institutional and accredited investors in a private placement.
Management states that the additional capital is intended to support the next phase of its AI-enabled InsurTech platform development, fund key technology initiatives, and bring new product capabilities to market. The financing also brings new long-term institutional investors into the shareholder base, which leadership believes can enhance market visibility and support its broader capital markets strategy.
Health In Tech, Inc. entered into a securities purchase agreement for a private investment in public equity (PIPE) covering 5,600,000 common shares at $1.25 per share, for expected gross proceeds of about $7.0 million before fees and expenses.
The company plans to use net proceeds to expand sales distribution, advance technology development, support new product development, and for general corporate purposes and working capital. The PIPE is expected to close on or about March 27, 2026, and the investors will receive resale registration rights for the shares.
Health In Tech, Inc. reported strong growth for 2025, with total revenue of $33.3 million and net income of $1.28 million, as the business scaled its AI-enabled InsurTech platform. Management highlighted that full-year revenue grew 71% year over year.
The company issued an upbeat 2026 outlook, guiding for revenue between $45 million and $50 million, implying approximately 35%–50% growth driven by expanding use of its underwriting marketplace and new features launched in January 2026. Adjusted EBITDA for 2025 was $4.11 million, and cash and cash equivalents were $7.67 million as of December 31, 2025.
Health In Tech, Inc. reported that its Chief Technology Officer, Imran Yousuf, was terminated from his position on November 25, 2025. The company states that the termination was without cause and was not the result of any disagreement regarding its operations, policies, or practices. This update focuses solely on the leadership change and does not describe any changes to the company’s strategy or business activities.
Health In Tech, Inc. furnished an earnings call transcript under Item 7.01. The call, held on November 10, 2025, covered financial and operating results for the quarter ended September 30, 2025. The transcript is included as Exhibit 99.1.
The information is deemed “furnished,” not “filed,” under the Exchange Act. A replay is available via the Company’s Investor Relations site through approximately February 8, 2026.
Health In Tech, Inc. (HIT) furnished an update on its quarterly results. The company reported that it issued a press release announcing results for the quarter ended September 30, 2025, and made that release available as Exhibit 99.1.
The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). The information in these items, including Exhibit 99.1, is expressly stated as “furnished” and not “filed” under the Exchange Act. The filing also includes customary forward‑looking statements language referring to risks described in the company’s periodic reports.
Health In Tech, Inc. (HIT) furnished an investor presentation under Regulation FD, making it available as Exhibit 99.1 to an 8-K. The materials are expressly deemed “furnished” and not “filed” under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference into other filings. The company also included customary forward-looking statements language outlining risks referenced in prior SEC reports.
Health In Tech, Inc. reported results of its 2025 annual stockholder meeting. As of the August 6, 2025 record date, 56,389,291 shares were outstanding, split between 44,689,291 Class A shares with one vote each and 11,700,000 Class B shares with ten votes each.
Stockholders representing about 99.33% of voting power, or 161,619,722 votes, were present, establishing a strong quorum. All five director nominees were re-elected with roughly 148 million votes cast in favor for each and minimal abstentions, with broker non-votes of 1,873,265.
Stockholders approved an amendment to the 2024 Equity Incentive Plan, raising the Class A share reserve for awards from 7,677,849 to 10,677,849 and allowing issuance of up to 2,000,000 Class B shares and related options to executive officers. They also ratified MaloneBailey, LLP as independent auditors for the year ending December 31, 2025, with 161,551,973 votes for, 33,314 against, and 34,446 abstentions.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for its two top executives tied to a specific new business initiative. On September 24, 2025, the company granted 80,000 shares of restricted stock to Chief Executive Officer Tim Johnson and 80,000 shares of restricted stock to Chief Financial Officer Linlin (Julia) Qian. These awards are meant to compensate them for work on a new initiative described as the “Initiative.”
Each grant is structured so that one third of the shares vest in monthly installments over 12 months starting when a letter of intent or memorandum of understanding is signed, another third vests monthly over 12 months starting when the Initiative reaches proof-of-concept or beta launch, and the final third vests monthly over 12 months starting at full commercial launch. The awards were made under the company’s existing Equity Incentive Plan and follow previously approved restricted stock award agreement terms.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for three senior executives tied to the development of two new programs, referred to as Program 1 and Program 2. Chief Executive Officer Tim Johnson was granted 17,000 shares for each program, Chief Financial Officer Linlin (Julia) Qian was granted 10,000 shares for Program 1 and 17,000 shares for Program 2, and Chief Technology Officer (Mo) Imran Yousuf was granted 3,500 shares for each program.
Half of each executive’s grant will vest in equal monthly installments over twelve months starting when the first of the two programs is successfully launched and fully operational in the marketplace. The remaining half will vest in equal monthly installments over twelve months starting when the other program is successfully launched and fully operational. These awards were made under the company’s Equity Incentive Plan and follow previously approved restricted stock award agreements.